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TC II deficiency: avoidance of false-negative molecular genetics
by RNA-based investigations
Abstract
Transcobalamin II (TC II) is a plasma transport protein for cobalamin. TC II deficiency can lead to
infant megaloblastic anemia, failure to thrive and to neurological complications. This report describes
the genetic work-up of three patients who presented in early infancy. Initially, genomic investigations
did not reveal the definite genetic diagnosis in the two index patients. However, analysis of cDNA from
skin fibroblasts revealed a homozygous deletion of exon 7 of the TC II gene caused by the mutation
c.940+303_c.1106+746del2152insCTGG (r.941_1105del; p.fs326X) in one patient. The other patients
were siblings and both affected by an insertion of 87 bp on the transcript which was caused by the
homozygous mutation c.580+624A>T (r.580ins87; p.fs209X). Additional experiments showed that
cDNA from lymphocytes could have been used also for the genetic work-up. This report shows that the
use of cDNA from skin fibroblasts or peripheral lymphocytes facilitates genetic investigations of
suspected TC II deficiency and helps to avoid false-negative DNA analysis.
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Abstract 
 
Transcobalamin II (TC II) is a plasma transport protein for cobalamin. TC II deficiency can 
lead to infant megaloblastic anaemia, failure to thrive and to neurological complications. This 
report describes the genetic work-up of three patients who presented in early infancy. Initially, 
genomic investigations did not reveal the definite genetic diagnosis in the two index-patients. 
However, analysis of cDNA from skin fibroblasts revealed a homozygous deletion of exon 7 
of the TC II gene caused by the mutation c.940+303_c.1106+746del2152insCTGG 
(r.941_1105del; p.fs326X) in one patient. The other patients were siblings and both affected 
by an insertion of 87bp on the transcript which was caused by the homozygous mutation 
c.580+624A>T (r.580ins87; p.fs209X). Additional experiments showed that cDNA from 
lymphocytes could have been used also for the genetic work-up. This report demonstrates that 
use of cDNA from skin fibroblasts or peripheral lymphocytes facilitates genetic investigations 
of suspected TC II deficiency and helps to avoid false negative DNA analysis. 
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Introduction 
 
Transcobalamin II (TCN2; TC II) is a plasma protein that is essential for absorption, transport 
and cellular uptake of cobalamin (Cbl, vitamin B12)1,2. Cbl is synthesized only by lower 
organisms and not by plants and animals. It accumulates in animals so that animal products 
are the only source of Cbl in the human diet. Intrinsic factor bound Cbl is recognized by ileal 
receptor proteins, cubilin and megalin, and enters the enterocytes via endocytosis. In ileal 
enterocytes, Cbl is dissolved from intrinsic factor and is bound to TC II prior to release into 
the blood system and distribution to target tissues3,4.  
Transcobalamin II deficiency (TC II deficiency, MIM #275350) leads to a lack of intracellular 
Cbl which manifests mainly in early infancy. Symptoms include megaloblastic anaemia and 
pancytopenia, vomiting, diarrhoea and early onset of failure to thrive, repeated infections, and 
mental retardation4,5,6,7,8. The disorder is inherited in an autosomal-recessive trait and was first 
described in 1971 in two siblings with megaloblastic anaemia and normal levels of serum 
Cbl9.  
Diagnosis can either be achieved by measurement of serum transcobalamin by an ELISA 
method10 or by genetic testing. Serum Cbl levels cannot serve as a diagnostic tool because 
they show as normal and most of serum Cbl is bound to haptocorrin (or: R-binder, formerly 
named transcobalamin I), a glycoprotein whose function is not fully understood4,5.  
In this study, the genetic work-up of two patients with typical early onset TC II deficiency is 
reported. Exon amplification and sequencing of the TCII gene was uninformative in regard to 
the definite genetic background in both patients. Skin fibroblast derived transcript analysis 
elucidated the genotypes. Additional experiments showed that lymphocytes could have been 
used as a source of the cDNA. Thus, transcript investigations using peripheral lymphocytes or 
skin fibroblasts can be regarded as an economical and straightforward approach for mutation 
screening in TC II deficiency. 
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Material and Methods 
 
Patients 
 
Patient 1 is the daughter of consanguineous Lebanese parents born at term (birth weight 3190 
g, length 50 cm, head circumference) after an uneventful pregnancy. Symptoms started at the 
age of three weeks with diarrhoea, vomiting, failure to thrive, as well as floppiness and 
muscular hypotonia. Investigations revealed pancytopenia (white blood cells 5100/µl, 
haemoglobin 5.7 g/dl, MCV 85 fl, platelets 72.000/µl, reticulocytes 6 %o), normal levels of 
serum Cbl (477 pg/ml), folic acid (9.3 ng/ml), and distinct changes of plasma amino acids:  
homocysteine 25.4 µmol/l (reference < 8), total cysteine 87 µmol/l (reference 200-460), 
methionine 11 µmol/l (reference 20-40), cystine 4 µmol/l (reference 20-60). Urine organic 
acids yielded a moderately elevated excretion of methylmalonic acid. Bone marrow aspiration 
showed a hypercellular bone marrow and as main pathology, a markedly altered 
erythropoiesis showing megaloblastic transformations and anomalies of nuclei forms 
suggestive of a Cbl or folic acid deficiency. TC II levels in serum were not established. Oral 
substitution of 15 mg folinic acid per day and intramuscular application of 1.5 mg 
hydroxycobalamin three times a week led to clinical and haematological recovery within two 
months. Follow up investigations at age 18 months showed a normal mental development but 
significant motor deficits (Münchener Funktionelle Entwicklungsdiagnostik). 
Patients 2 and 3 are offspring of consanguineous Turkish parents. The elder sister (patient 2 in 
this report) became symptomatic at the age of six weeks with failure to thrive and 
pancytopenia (white blood cells 580/µl, haemoglobin 6.3 g/dl, platelets 119.000/µl). Bone 
marrow aspiration showed a reduced erythropoiesis and thrombopoiesis but an increased 
granulopoiesis. At eight weeks, urine organic acid analysis revealed massively elevated 
excretion of methylmalonic acid, methylcitrate, and 3-OH-proprionate. As with patient 1, TC 
II levels in serum were not established before initiation of treatment. Application of oral folic 
acid and intramuscular hydroxycobalamin (at start 1 mg daily) led to the normalization of 
clinical symptoms and urine metabolites within three weeks as well as haematological 
abnormalities within three months. Symptoms in patient 3 started at week six of life with 
vomiting and failure to thrive. Laboratory investigations showed an anaemia (haemoglobin 
7.5 g/dl), hyperhomocysteinemia (149 µmol/l) with a low normal methionine (15 µmol/l), and 
a massively elevated excretion of methylmalonic acid in urine. Serum Cbl was normal (864 
pg/ml). Based on the family history, an oral supplementation of folic acid and parenteral 
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hydroxycobalamin (at start 1 mg daily) was initiated which led to a full recovery within eight 
weeks. A follow-up at age of nine and eleven years, respectively, showed a normal 
psychomotor development in patients 2 and 3.  
 
For molecular genetic diagnostics, blood samples of patients were taken and skin fibroblasts 
from patients 1 and 2 were put into culture after informed consent of parents was obtained. 
For the purpose of lymphocyte isolation and subsequent cDNA synthesis, blood samples of 
two healthy German individuals were collected after written consent for the genetic study was 
obtained. In addition, DNA samples of 50 healthy German individuals were used as controls 
after written consent for the use of the samples for scientific purposes was obtained. 
 
DNA isolation and cDNA synthesis 
 
Genomic DNA was extracted from patient’s whole blood cells by a standard method 
(QIAamp blood kit, Qiagen, Hilden, Germany).  
Total RNA was isolated from cultured fibroblasts of the patients (RNeasy Mini Kit, 
Invitrogen, Groningen, The Netherlands) to synthesise single-stranded cDNA according to 
manufacturer’s recommendations (First Strand cDNA Synthesis Kit for RT-PCR, Boehringer 
Mannheim, Mannheim, Germany). cDNA from peripheral lymphocytes of two healthy 
controls was produced by the same method.  
 
Mutation analysis using DNA and cDNA 
 
Primers were designed binding in the flanking intronic regions of each of the nine coding 
exons (see table 1). PCR amplification was performed at an annealing temperature of 64°C 
using Taq-Polymerase (Boehringer Mannheim, Mannheim, Germany) prior to direct 
sequencing of PCR-products using the ABI Prism 3700 DNA Sequencer (Applied 
Biosystems, Foster City, CA). 
A full-length PCR of the TC II transcript was performed at an annealing temperature of 62°C 
(expected size 1458 bp; primers given in table 1). This was later repeated using cDNA 
derived from uncultured peripheral lymphocytes obtained from control subjects. PCR 
products were purified following agarose gel electrophoresis and subjected to direct 
sequencing using the ABI Prism 3700 DNA Sequencer (Applied Biosystems).  
 5 
For characterization of the exact size of the assumed deletion in patient 1, intronic primers for 
the region of interest were used for PCR amplification of DNA at an annealing temperature of 
65°C (primer-forward 5’-CAATCTGCTGCGCACCCATT, primer-reverse 5’-
CAGGTGTTAGCCATCACACTC). PCR products were directly sequenced as above. For the 
amplification of the region surrounding the inserted sequence of intron 4 in patient 2, an 
annealing temperature of 64°C was used for the forward-primer for exon 4 and reverse-primer 
for exon 5, respectively. 
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Results 
 
Direct sequencing of the nine coding exons of the TC II gene including the flanking intronic 
regions did not reveal the definite genotype in either of the two index-patients.  
In patient 1, PCR amplification of exon 7 did not yield a product indicating a possible deletion 
in this genomic region. Based on these results and on the strong clinical and biochemical 
suspicion, it was decided to proceed with RNA diagnostics.  
RT-PCR of skin fibroblast derived cDNA yielded full length TC II fragments that were about 
200bp shorter in size in patient 1 and about 80bp longer in patient 2 when compared to 
controls. Direct sequencing of full length TC II RT-PCR products revealed a homozygous 
deletion of exon 7 of the TC II transcript in cDNA derived from patient 1. For breakpoint 
characterization, PCR amplification with a forward primer located in intron 6 and a reverse 
primer in intron 7 was performed and yielded products that were about 2000bp shorter than 
healthy controls. Direct sequencing indicated breakpoints at position c.940+303 in intron 6 
and at position c.1106+746 in intron 7, respectively. This resulted in a genomic deletion of 
2152bp and an insertion of CTGG (c.940+303_c.1106+746del2152insCTGG) as well as a 
subsequent loss of exon 7 (r.941_1105del) in a homozygous state (Fig. 1a). Loss of exon 7 
affects the transcript with a frameshift and results in a premature stop of translation at codon 
326 (fs326X). Both parents were shown to be heterozygous carriers of the respective 
mutation.  
In patient 2, sequencing of the full length TC II transcript revealed a homozygous insertion of 
87bp between exons 4 and 5 with the inserted sequence being identical to a sequence in intron 
4. PCR amplification and sequencing of part of intron 4 revealed the mutation c.580+624A>T 
in a homozygous state. This mutation generates a new donor-splice-site leading to activation 
of a cryptic acceptor-splice-site and results in the insertion of the transcript (Fig. 1b) and a 
premature stop of translation within the inserted region (r.580ins87bp; fs209X). Direct 
sequencing of 100 control chromosomes did not reveal the nucleotide exchange 
c.580+624A>T. This mutation was also confirmed in DNA from patient 3 in a homozygous 
state while both parents were found to be heterozygous for the respective mutation. 
In addition, cDNA derived from uncultured peripheral lymphocytes of controls was used for 
amplification of the full-length TC II transcript. This yielded a specific RT-PCR-product that 
was successfully subjected to direct sequencing indicating that transcript analysis using 
peripheral blood cells is feasible. 
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Discussion 
 
In this paper, we have added three patients to the short list of reported patients suffering from 
TC II deficiency. The results of the patients reported in this paper follow published 
characteristics4 in respect to the clinical course and most laboratory results. However, the 
finding of the hypercellular bone marrow in patient 1 is unusual and might indicate a possible 
variability of this sign in TC II deficiency. As well documented in all reports, 
supplementation of Cbl is an effective treatment for this condition. This is noteworthy, given 
the lack of its transporter in blood. The feasibility of this treatment is not fully understood.  
However, it might be explained by some level of residual activity of the mutated protein or by 
an alternative transport of Cbl in blood by binding to haptocorrin, albumin or to other 
proteins. It should be noted that the route of administration of Cbl is still under discussion. 
While the patients reported here were treated by parenteral Cbl, oral treatment, if carefully 
monitored4,11 , might be similarly effective. 
Although known as a clinical entity since 19719 and despite description of first mutations in 
the TC II gene as early as 199412, there are only a total of six mutations found in eight patients 
reported in the literature7,12,13,14. There is considerable genetic heterogeneity of TC II 
deficiency comprising nonsense mutations12, deletions13, RNA editing7, and a mutation 
affecting a splice site14 (details of mutations are provided in table 2). 
The human TC II gene on chromosome 22q11.2-qter has been fully cloned and characterized 
in 199515,16 allowing for genetic investigations based on DNA amplification. However, the 
patients described in this study were not fully informative when the nine coding exons 
including flanking intronic regions of the TC II gene were sequenced. Based on the clinical 
and biochemical strong impression of TC II deficiency as being the underlying disorder in the 
patients, we proceeded by skin fibroblasts derived RNA investigations in order to confirm the 
suspected diagnosis. It has yet to be emphasized that serum studies of transcobalamin could 
have been performed to confirm the suspected diagnosis. 
According to DNA and RNA studies, patient 1 was found to be affected by a homozygous 
deletion of 2152bp and an insertion of four nucleotides (CTGG) resulting in the loss of exon 7 
of the TC II gene. This mutation causes a frameshift with a premature stop of translation at 
codon 326 and can, therefore, be considered as disease causing. Patients 2 and 3 are affected 
by an intronic nucleotide exchange. This creates a novel intronic donor splice site leading to 
use of a cryptic intronic acceptor splice site and a consecutive insertion of 87bp into the TC II 
transcript. As the inserted fragment carries an in-frame stop codon at position 209, this 
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mutation results also in a truncated TC II protein and can be regarded as disease causing. This 
intronic mutation adds to the hitherto described genetic heterogeneity of TC II deficiency as 
mentioned above.  
To facilitate future genetic investigations, additionally we investigated RNA from control 
lymphocytes as an alternative which allows waiving skin biopsies. Hereby, the feasibility of 
this source of material for genetic work up of TC II deficiency could be demonstrated.  
In conclusion, this study reports on three patients with TC II deficiency in which RNA based 
molecular genetics but not exon amplification and sequencing of DNA led to the definite 
genetic diagnosis. We show that lymphocytes can be used for full-length cDNA analysis to 
complement genomic investigations facilitating genetic diagnostics of TC II deficiency and to 
avoid false negative DNA investigations. 
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Legend to table 1:  
Table 1 provides sequences of primers used in the present study for amplification of the nine 
coding exons of the TC II gene including flanking intronic regions and of the full-length TC II 
transcript. Also, expected sizes of PCR products are given. bp: base pairs. 
 
Legend to table 2: 
Summary of the mutations reported in the TCII gene. Genbank entry NC_000022 has been 
used as reference. 
 
Legend to Figure 1: 
Illustration of the effect of the mutations both on genomic DNA and on cDNA. Grey boxes 
indicate coding exons with numbering given. Light grey triangles display the result of the 
genomic mutation on cDNA. 
Figure 1a: Dashed white box indicates exon 7 which was found to be deleted in patient 1. 
Vertical arrows indicate location of breakpoints of the deletion. 
Figure 1b: Vertical arrow indicates location of the intronic nucleotide exchange leading to 
creation of a novel intronic donor splice site. ag: cryptic intronic acceptor splice site; gt: novel 
intronic donor splice site; bp: base pairs. 
Table 1 
 
Exon Primer forward 5’ – 3’ Primer reverse 5’ – 3’ PCR product size
(bp) 
 
1 AGCGGTGACCAGCTGTGGTC 
 
CTCATCCTATGCCCTAGCCA 231 
2 GAGAAGGCCCTGGTAACGTC 
 
GCCCAAACTAGTACCCAAGT 349 
3 GGTGCTGTAAGCAGGCTTAC 
 
AGAATATCATCTGATGAGCC 296 
4 GCGTGTTGGAAAGTGCAGGC 
 
GAGGTCATCAGTGCAGACCT 319 
5 TCCATAGCTACAAGGGCCTG 
 
TCCCCAGGGTGGCCATGGCT 303 
6 GGTCAGGTGCTGGAACACCT 
 
AATGGGTGCGCAGCAGATTG 313 
7 ATCCAGGCTCTCTGTCCTCA 
 
CTGTGACCCTGTTATCAGGC 283 
8 GGACAACAGCCACCTCTTCT 
 
AGCCTCTTGGCTGAGTAAGC 225 
9 GGTGCGATATTCTGCCCAAT 
 
CAGGCGAGTTCCTGTTCCAG 200 
cDNA AGCTGTGGTCAGGAGAG 
 
GAGGGTAGAAGCCTAGG 1458 
 
 
Table 2 
 
 
 
Exon 
affected 
mRNA gDNA Effect reference 
2 r.172delC c.172delC p.fs85X 12 
3 r.387delA c.387delA p.fs206X 12 
8 r.1110T>G c.1110T>G p.Tyr370X 12 
6 r.927_930del c.926_931del4 p.fs358X 13 
1 r.31C>G not present  p.Leu11Val 7 
1 r.62G>A not present p.Cys21Tyr 7 
2 r.79G>A not present p.Asp27Asn 7 
2 r.145C>T not present p.His49Tyr 7 
2 r.254T>A not present p.Leu85Gln 7 
2 r.257G>A not present p.Gly86Glu 7 
4 r.472G>T not present p.Gly158Cys 7 
3 r.347_427del c.427+2T>G p.Cys116_Ile142delGly143Trp 14 
4,5 r.580ins87 c.580+624A>T p.fs209X This study 
7 r.941_1105del c.940+303_c.1106+746del2152insCTGG p.fs326X This study 
 
